If our hypothesis is correct that mTOR inhibition with sirolimus can improve RFS, while simultaneously providing adequate immunosuppression, patients with HCC that receive a LT could expect a longer and better quality of life. This evidence concerns the gene MTOR and hepatocellular carcinoma.